Diabetic macular edema (DME) is one of several therapeutic areas in which new data are emerging.

Results from 5 phase III studies on retinal vein occlusion (RVO) were recently announced.

With regards to uveitis, there is a large amount of new clinical trial data that need to be communicated to the retina community. Because intraocular corticosteroids need to be administered frequently and cause significant side effects, including cataracts and glaucoma, corticosteroid implants may become a more viable treatment option. Data from recently completed studies need to be communicated to retina specialists. This CME activity is designed to help retina specialists aggregate, interpret, and apply the new data to their clinical practice.